CRDF - Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC
PR Newswire
SAN DIEGO , March 22, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that CEO Mark Erlander , Ph.D., has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28 th – 30 th from 9:00 AM - 5:00 PM EDT .
Details on the presentation can be found below.
Presentation Format: |
Fireside Chat |
Presentation Date: |
March 28, 2022 |
Presentation Time: |
2:30 PM ET |
In addition to the fireside chat, Dr. Erlander will also provide a pre-recorded overview of Cardiff Oncology's clinical and corporate strategy. The pre-recorded presentation will be available throughout the duration of the conference, which will be streamed live on M-Vest. To attend, sign up to become an M-Vest member here .
A replay of the fireside chat will be available by visiting the " Events " section on the investor page of the Cardiff Oncology website after the conference's conclusion.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SOC) therapeutics in clinical programs targeting indications such as KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SOC. For more information, please visit https://www.cardiffoncology.com
Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652
vkelemen@cardiffoncology.com
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Amy Jobe , Ph.D.
LifeSci Communications
315-879-8192
ajobe@lifescicomms.com
SOURCE Cardiff Oncology, Inc.
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.